| Stem Cells |
|
Adult stem cells have properties that make them attractive drug candidates for tissue regeneration. Stem cells are expandable to large amounts and they are able to turn into various cell types and therefore can repair different types of tissue. The technologies developed by Pharmicell enhance these natural properties of stem cells. The stem cell compositions developed by Pharmicell Europe are thoroughly characterized and designed for the introduction of revolutionary new treatments for specific disease processes, including cerebral stroke, heart failure and myocarditis, graft rejection, autoimmune disorders, skin rejuvenation and plastic and cosmetics surgery. Pharmicell Europe is using the highest standards for the manufacturing of stem cells to provide safe and efficient products. The ongoing R&D projects focus on improving the cell’s characteristics and their activities to make them even more useful for therapies. Some of these R&D projects are performed in animals provided the basis for the clinical trials track. The clinical development of stem cell drugs is aimed at four major fields: The cardiac program focuses on the clinical improvement of heart failure patients, suffering from myocarditis or heart infarction. The neurodegeneration program focuses on limiting neurological damage after cerebral stroke and the support of nervous system. The organ transplantation program aims at preventing graft rejection by using stem cell drugs to modulate the immune system. In the plastic-aesthetic therapy program stem cell products are used to rejuvenate ageing skin or repair damaged skin. This includes skin damage caused by autoimmune problems such as atopy.  Stem Cell Sources |